Strides Arcolab Limited Subsidiary Onco Therapies Gets US FDA Approval for Paclitaxel Injection

Published: Oct 03, 2011

Onco Therapies Limited, a wholly owned subsidiary of Strides Arcolab Limited has received the US FDA approval for paclitaxel injection USP, 6 mg/ ML packaged in 30 mg/ mL, 100 mg/16.7 mL and 300 mg/ 50 ML multiple dose vials. Paclitaxel is among the products in the drug shortage list of the American Society of Health-System Pharmacists and the US FDA. According IMS data, the US market for generic Paclitaxel approximated US$ 46 Million. The Company will launch the product immediately.

Back to news